Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Sanofi ditches mRNA vaccine for COVID-19

by Ryan Cross
October 1, 2021 | A version of this story appeared in Volume 99, Issue 36

 

Just 2 months after agreeing to spend $3.2 billion to acquire Translate Bio, Sanofi says it will stop developing Translate’s messenger RNA (mRNA) vaccine for COVID-19. Although the vaccine looked promising in its Phase 1/2 clinical trial, Sanofi says it doubts that it would be able to finish tests of the shot in time to help with the pandemic. Instead, the firm will focus on developing mRNA vaccines for the flu and other diseases. Sanofi will also continue developing its own protein-based vaccine for COVID-19, which is in a Phase 3 trial.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.